Abstract
Chronic opioid treatment of stably μ-opioid receptor transfected human mammary epidermoid A431 carcinoma cells (clone A431/μ13) results in sensitization of adenylyl cyclase (AC), a cellular adaptation associated with drug dependence. Up-regulation of AC is characterized by significantly increased levels of both basal and post-receptor-stimulated effector activities, which develop without any apparent change in the quantity of stimulatory G proteins and the maximum catalytic activity of AC. Here, we report that detergent extracts from membranes of chronically morphine-treated (10 μm; 2 days) A431/μ13 cells display higher stimulatory AC activities as assessed in the S49cyc −reconstitution assay. This finding is most likely due to an increased functional activity of Gsα because the addition of exogenous Gβγ subunits, which per sestimulate AC in S49cyc − membranes, failed to affect the difference in reconstitutive AC activity. Moreover, both chemical depalmitoylation by hydroxylamine and inhibition of palmitoyl-CoA transferase in vivo by tunicamycin treatment increased the reconstitutive activity of detergent extracts and eliminated the differences between native and opioid-dependent cells, indicating that the increase in stimulatory activity is due to depalmitoylation of Gsα. Indeed, metabolic labeling studies with [3H]palmitic acid revealed that chronic opioid treatment reduces considerably the fraction of palmitoylated Gsα in the plasma membrane. Furthermore, high affinity [3H]forskolin binding experiments demonstrated that depalmitoylated Gsα is able to associate directly with AC during the state of opioid dependence even without preceding receptor activation. These results suggest that post-translational palmitoylation of Gsα provides a potential regulator of transmembrane signaling. Moreover, accumulation of the depalmitoylated form of Gsα in the plasma membrane as reported herein may contribute to the increase in stimulatory AC signaling, as is characteristic for the state of opioid dependence.
Footnotes
- Received February 10, 1997.
- Accepted August 11, 1997.
-
Send reprint requests to: Dr. Hermann Ammer, Institute of Pharmacology, Toxicology and Pharmacy, University of Munich, Koeniginstrasse 16, 80539 München, Germany. E-mail:ammer{at}pharmtox.vetmed.uni-muenchen.de
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|